RGX-104 is an oral, selective LXR (Liver-X Nuclear Hormone Receptor) agonist, and a first-in-class immunotherapy agent. It activates the expression of the ApoE gene and reverses the immunosuppressive effects of cancer by targeting the LXR/ApoE pathway that regulates the innate immune response to cancer. This next-generation therapy has two key effects on the innate immune system that drive tumor immunity: it depletes myeloid-derived suppressor cells (MDSCs) and stimulates dendritic cells (DCs). MDSCs block the ability of T cells to become active, while stimulated DCs are required for proper activation (priming) of T cells.

KEYWORDS: RGX-104 | Supplier | LXR agonist | RGX104 | RGX 104 | SB-742881 | SB742881 | CT-RGX104 | CAS [610318-54-2] | Metabolism | LXR | Agonist | Receptors